BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 09:30PM GMT
Release Date Price: $62.33 (+0.61%)
Paul Choi
Goldman Sachs Group, Inc., Research Division - Equity Analyst

Okay, everyone. We'll continue with the next session. I'm Paul Choi, the SMid-cap biotechnology analyst here at Goldman Sachs. And it's my pleasure to have BridgeBio Pharma present here. Joining us from BridgeBio is Neil Kumar, CEO.

What we'll do as in prior sessions, is I'll turn it over to Neil, maybe for some opening remarks or comments on the shape of what BridgeBio is doing here in 2021 and 2022, and then we'll go into Q&A. If investors along the way have any questions, as in prior sessions, please feel free to submit them through the webcast portal. Alternatively, you can e-mail them to me and, time permitting, I'll ask them of Neil. And with that, I'll turn it over to Neil.

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Great. Well, thanks, Paul, so much for the opportunity to participate in the conference. I really appreciate the time and the chat today. I'll make my opening comments brief because it'd be great to get into the Q&A.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot